Claritas Pharmaceuticals Inc V.CLAS.H

RE:A fool and their money are soon parted

[whisky11]

Jshaw9]Too bad some can't see the fool in the mirror 
RS coming, apparently can't raise money without it... keep your hopes up! Maybe some day they will start doing things differently than they did with KLY

brought to you by a MM paid basher and shorter 


whisky11: look dude, you're bubbling something about  half a cent up or down.
We are talking about R-107 and it's potential ea. big money for investors.
I'm not here for five cents a share or $0.80 a share. R 107 worked very well on large animals.
R-107 is approved for testing on humans, it means it's safe to administrate it to volunteers, and that's why I'm here.

.R-107 is Claritas’ patented nitric oxide-releasing compound. Nitric oxide is the immune system’s first line of defense against viral infection. When a viral threat is present, white blood cells migrate to the area of infection and release a burst of nitric oxide that crosses into the infected cell to inactivate the virus. R-107 is designed to augment the body’s natural release of nitric oxide to significantly hasten and strengthen the body’s ability to eliminate the virus.

There is an extensive body of in vitro and in vivo data demonstrating the ability of nitric oxide to prevent the replication and transmission of various RNA viruses, such as those that cause COVID-19 infection, as well as viruses that cause the influenza and the common cold.

Unlike nitric oxide, which is a gas that must be administered by a trained respiratory therapist using special delivery equipment, R-107 is a liquid that may be easily administered orally in a capsule, or nasally though use of a spray, or by intramuscular injection. Due to its ease of administration, R-107 may overcome the challenges inherent in administration of nitric oxide gas, and transform nitric oxide therapy into a potentially best-of-care treatment for COVID-19 infection, and potentially other viral infections.